Skip to main content
SpringerLink
Log in

Afatinib

Thrombocytopenia and rash: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kang L, et al. CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations. Frontiers in Oncology 13: 1094195, Jan 2023. Available from: URL: http://doi.org/10.3389/fonc.2023.1094195

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib. Reactions Weekly 1952, 31 (2023). https://doi.org/10.1007/s40278-023-37124-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-37124-1

Search

Navigation